MedTrace Logo

Research of Intensive Lifestyle Intervention for PCOS Patients With IGT

NCT02446834 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-10-17

No results posted yet for this study

Summary

Compare the efficacy between intensive lifestyle intervention and drugs (GLP-1 Receptor Agonists, metformin and acarbose) for PCOS patients with early onset diabetes in their metabolic and reproductive abnormalities treatment; clear the treatment effect and mechanism of intensive lifestyle intervention to PCOS.

Conditions

  • Polycystic Ovary Syndrome

Interventions

BEHAVIORAL

intensive lifestyle intervention

3 months low GI diet and exercise

DRUG

GLP-1 Receptor Agonists

Use GLP-1 Receptor Agonists 3 months to treat PCOS

DRUG

Metformin

Use metformin 3 months to treat PCOS

DRUG

Acarbose

Use acarbose 3 months to treat PCOS

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Tao Tao, MD · RenJi Hospital Department of Endocrinology and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
14 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-12-31
Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446834 on ClinicalTrials.gov